News
PCV-LITE: Promising Preclinical data on CMS in combination with PCV
https://doi.org/10.1016/j.vaccine.2025.126893
This achievement is made possible with the excellent collaboration Laboratory of Medical Immunology, Radboud University Medical Center to show vaccine improvement of the current Pneumococcal Conjugate Vaccines.
LiteVax has received regulatory approval for a Clinical Trial Application for PCV-LITE in healthy adults. This milestone marks the next step in evaluating our CMS adjuvant in a pneumococcal conjugate vaccine (PCV) study, aiming to enhance immune responses with fractional dosing.
This marks a significant step in advancing our adjuvant technology into the clinic.
https://doi.org/10.3390/vaccines12091036
This achievement wouldn't have been possible without the excellent and enjoyable collaboration within the INDIGO consortium, uniting public and private R&D partners to develop improved influenza vaccines. It's inspiring to be part of such an innovative team driving progress in global health!
INDIGO, a consortium of public and private R&D organizations for development of improved influenza virus vaccines, has started a Phase 1b trial with a novel, adjuvanted, seasonal influenza vaccine. The phase 1b clinical study is a follow-up of the first-in-human trial, and will evaluate the safety, immunogenicity and immunological mechanisms of the novel LiteVax Adjuvant added to a full dose of licensed influenza vaccine in participants aged 18-50 and > 60 years.
Development project for a novel bacterial vaccine concept in Urinary Tract Infections Targeting O-linked glycosylated antigen Potency and Integrity Assays”
Partners: GlyProVac (Odense, DK) Spectralys (Brussels, BE),
LiteVax (Oss, NL) and Odense University Hospital (DK)
Duration: April 2024 - March 2027
INDIGO, a consortium of public and private R&D organisations for development of improved influenza virus vaccines, has started a Phase 1 trial with a novel, adjuvanted, low-dose seasonal influenza vaccine. Safety, tolerability, and immunogenicity of TETRALITE, a combination of 1/5th of a dose of a licensed influenza vaccine and the novel LiteVax Adjuvant, will be investigated in healthy subjects.
“Next Generation Vaccines for Multi-Resistant Bacteria”.
Partners: Proxi Biotech ApS, Cellvax SAS, LiteVax B.V.
“Safety and immunogenicity of a CMS-adjuvanted, newly developed toxoid-based vaccine against C. difficile infection in non-rodent species”. Partners: Proxi Biotech ApS, Institut national de la Recherche agronomique (INRA), LiteVax B.V.
“Immunogenicity of recombinant SARS-CoV-2 Spike Protein Subunits plus a novel, potent adjuvant in Non-Rodent Species”; Possibilities of a Single-Low-Dose Vaccine against Coronavirus Infection”
Partners: ImmunoPrecise Antibodies, Institut de Recerca i Tecnologia Agroalimentàries (IRTA), LiteVax B.V.
“Effective and affordable flu vaccine for the globe”
LiteVax receives EU Horizon 2020 grant for the development of a next generation of flu vaccines for the globe.
“Treatment enabled by REcombinant Advanced immunotherapy Technologies for HER2 positive tumours”.
Partners: AdaptVac, University of Copenhagen, Expres2ion, Biomedical Primate Research Centre, LiteVax.
For the third time in 2018 LiteVax visited India and joined the Dutch Trade Mission. Prime Minister Mark Rutte and four Ministers were present to support the strategic relationships and economic cooperation. During this important event LiteVax signed 3 MoU's with Indian companies for vaccine development.
One of the predecessor of LiteVax LVX adjuvant proved to be superior to Freunds’ Complete/Incomplete Adjuvant in large animal species (PMID: 27693642)
